



## Common Drug Review \*

### Submission Status

<b>Product:</b>	BuTrans		
<b>Generic Name:</b>	buprenorphine transdermal patch		
<b>Manufacturer:</b>	Purdue Pharma		
<b>Indication:</b>	Pain, persistent (moderate intensity)		
<b>Submission Type:</b>	Initial		
<b>Date Submission Received:</b>	2010-Oct-15	<b>Date NOC Issued:</b>	2010-Mar-05
<b>Targeted CEDAC Meeting:</b>	2011-Mar-23	<b>Priority Review Granted:</b>	Not Requested

Phase	Target Time (Business Days)	Target Date **	Actual CDR Date	Comments	
1	Submission deemed complete	5	2010-Oct-22	2010-Oct-22	Submission deemed complete.
2	Patient group input submission received		2010-Nov-05	2010-Nov-05	Patient group submissions received.
3	CADTH Reviewers' Reports sent to Manufacturer	45	2011-Jan-13	2011-Jan-17	New date to send to manufacturer 2011-Jan-17.
4	Comments from Manufacturer on Reviewers' Reports Received by CADTH	7	2011-Jan-24	2011-Jan-26	New date for manufacturers comments 2011-Jan-26.
5	CEDAC Meeting		2011-Mar-23	2011-Mar-23	
6	CEDAC Recommendation *** Sent to Drug Plans, ACP and Manufacturer	5 to 7	2011-Mar-30	2011-Apr-01	New date: 2011-Apr-1. In accordance with the Procedure for Common Drug Review recommendation released 7 business days after CEDAC.
7	Embargo Period **** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation	10	2011-Apr-13	2011-Apr-15	New date: 2011-Apr-15. Request for reconsideration received 2011-Apr-15. New information received in Request for Reconsideration. Resubmission received 2011-May-09. Review stopped.
8 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5			
OR					
8 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
OR					
8 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
9	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

\* Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.

\*\* The Formulary review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on [www.cadth.ca](http://www.cadth.ca).

\*\*\* The Procedure for Common Drug Review, section 8.3.3a, states "...the CEDAC recommendation will be sent to the Manufacturer, ACP and to the drug plans within five (5) to seven (7) business days following the CEDAC meeting...". The original target date is based on five (5) business days.

\*\*\*\* The Recommendation is held in confidence and not acted upon until after CADTH has issued the notice of Final Recommendation.